cervical cancer
Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial
Anika Sharma
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
SG Tylor
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
Cervical Cancer: Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity
SG Tylor
The combination of the novel bifunctional fusion protein SHR-1701 with bevacizumab (BP102) and platinum-doublet chemotherapy has shown promising results in ...
In order to provide access to cervical cancer screening tools in low- and lower-middle income countries, Roche received WHO prequalification for the Cobas HPV test
SG Tylor
Source – Roche On June 13, 2023, the World Health Organisation (WHO) prequalified the Cobas Human Papillomavirus (HPV) test for ...
